Company intelligence / Profile preview

Orqis Medical

Lake Forest, California, United Statesbiospace.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Orqis Medical developed minimally invasive devices to improve cardiac performance in patients with heart failure by augmenting aortic blood flow. The flagship product, the Cancion System, was evaluated in the MOMENTUM pivotal trial. While the trial did not meet its primary composite efficacy endpoint, it demonstrated statistically significant improvement in cardiac performance compared to drug treatment alone. The system received CE mark approval and was available outside the U.S., while an implantable version called Exeleras was under development.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

Cancion System

Phase 3

Indications: Acute decompensated heart failure

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Orqis Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orqis Medical.

Explore the full profile